Creative Medical Technology (CELZ) 10-K 13 Feb 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 13, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	1,187,953
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 0
Trading Symbol	CELZ
Entity Common Stock, Shares Outstanding		105,013,750

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash	$ 221,868	$ 100
Stock subscription receivable	0	49,500
Total Current Assets	221,868	49,600
OTHER ASSETS
Licenses, net of amortization	100,644	0
TOTAL ASSETS	322,512	49,600
CURRENT LIABILITIES
Accounts payable	66,385	0
Accrued expenses	4,879	0
Notes payable - related party - current	100,000	0
Management fee payable - related party	280,000	0
Advances from related party	2,600	100
Total Current Liabilities	453,864	100
LONG TERM LIABILITIES
Notes payable - related party, net of current portion	25,000	0
Accrued expenses, net of current portion	1,439	0
TOTAL LIABILITIES	480,303	100
Commitments and contingencies
STOCKHOLDERS’ (DEFICIT) EQUITY
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value, 600,000,000 shares authorized; 105,013,750 and 32,010,000 shares issued and outstanding, respectively	105,014	32,010
Additional paid-in capital	503,767	17,990
Accumulated deficit	(766,572)	(500)
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY	(157,791)	49,500
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY	$ 322,512	$ 49,600

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	600,000,000	600,000,000
Common Stock, Shares, Issued	105,013,750	32,010,000
Common Stock, Shares, Outstanding	105,013,750	32,010,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2015	Dec. 31, 2016
REVENUES	$ 0	$ 0
OPERATING EXPENSES
Research and development	0	85,334
General and administrative	500	664,984
Amortization of patent costs	0	9,356
TOTAL EXPENSES	500	759,674
OTHER INCOME/(EXPENSE)
Interest expense, related party	0	(6,398)
OPERATING LOSS	(500)	(766,072)
NET LOSS	$ (500)	$ (766,072)
BASIC AND DILUTED LOSS PER SHARE	$ 0	$ (0.01)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	32,010,000	94,006,533

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)	Total	Patents [Member]	Licensing Agreements [Member]	Preferred Stock [Member]	Preferred Stock [Member]Patents [Member]	Preferred Stock [Member]Licensing Agreements [Member]	Common Stock [Member]	Common Stock [Member]Patents [Member]	Common Stock [Member]Licensing Agreements [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Patents [Member]	Additional Paid-in Capital [Member]Licensing Agreements [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Patents [Member]	Accumulated Deficit [Member]Licensing Agreements [Member]
Balance at Dec. 29, 2015	$ 0			$ 0			$ 0			$ 0			$ 0
Balance (In Shares) at Dec. 29, 2015				0			0
Common stock issued for cash	50,000			$ 0			$ 32,010			17,990			0
Common stock issued for cash (In Shares)				0			32,010,000
Net loss	(500)			$ 0			$ 0			0			(500)
Balance at Dec. 31, 2015	49,500			$ 0			$ 32,010			17,990			(500)
Balance (In Shares) at Dec. 31, 2015				0			32,010,000
Common stock issued for cash	470,000			$ 0			$ 4,700			465,300			0
Common stock issued for cash (In Shares)				0			4,700,000
Common stock issued for cash to related party	30,000			$ 0			$ 300			29,700			0
Common stock issued for cash to related party (In Shares)				0			300,000
Common stock issued for ED Patent		$ 100,000	$ 1,000		$ 0	$ 0		$ 64,667	$ 323		$ 35,333	$ 677		$ 0	$ 0
Common stock issued for ED Patent (In Shares)					0	0		64,666,667	323,333
Acquisition of Creative Medical Technology Holdings, Inc as part of recapitalization	(44,784)			$ 0			$ 18,114			(62,898)			0
Acquisition of Creative Medical Technology Holdings, Inc as part of recapitalization (In Shares)				0			18,113,750
Cancellation of shares outstanding	0			$ 0			$ (15,100)			15,100			0
Cancellation of shares outstanding (In Shares)				0			(15,100,000)
Stock-based compensation	2,565			$ 0			$ 0			2,565			0
Net loss	(766,072)			0			0			0			(766,072)
Balance at Dec. 31, 2016	$ (157,791)			$ 0			$ 105,014			$ 503,767			$ (766,572)
Balance (In Shares) at Dec. 31, 2016				0			105,013,750

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2015	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (500)	$ (766,072)
Adjustments to reconcile net loss to net cash from operating activities:
Stock based compensation	0	2,565
Amortization	0	9,356
Changes in assets and liabilities:
Accounts payable	0	22,601
Accrued expenses	0	6,318
Management fee payable	100	280,000
Net cash (used) by operating activities	(400)	(445,232)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of licenses	0	(10,000)
Net cash (used) by investing activities	0	(10,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash received from notes payable - related party	0	125,000
Cash received from subscription receivable	0	49,500
Proceeds from sale of common stock	0	500,000
Related party advances	0	2,500
Contributed capital	500	0
Net cash provided from financing activities	500	677,000
NET INCREASE IN CASH	100	221,768
BEGINNING CASH BALANCE	0	100
ENDING CASH BALANCE	100	221,868
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	0	0
Cash payments for income taxes	0	0
NON-CASH FINANCING ACTIVITIES:
Accounts payable assumed in reverse merger	0	43,784
Fair value of warrants issued in private placement	0	32,530
Licensing Agreements [Member]
NON-CASH FINANCING ACTIVITIES:
Stock Issued	0	1,000
Patents [Member]
NON-CASH FINANCING ACTIVITIES:
Stock Issued	$ 0	$ 100,000

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	Organization - Creative Medical Technology Holdings, Inc., formerly Jolley Marketing, Inc. (the “ Company CMTH CMT a. CMT advanced $ 25,000 b. The Company exchanged 97,000,000 6.466666 c. As part of the acquisition, CMT purchased 15,100,000 5,000 d. The shareholders of CMT acquired voting and operating control of the Company after the recapitalization; and e. The financial operations of the Company, as reported after the merger, are the historical information of CMT. CMT was incorporated in the State of Nevada on December 30, 2015 (“ Inception On September 14, 2016, CMT filed a certificate of organization for Amniostem LLC, a Nevada limited liability company and wholly owned subsidiary of CMT. Amniostem, LLC was formed to create and/or license intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. With this, management intends to address what it believes are unmet medical needs through development and commercialization of amniotic fluid stem cell based technologies. Management intends to seek in licensing opportunities as well as create intellectual property in-house for this newly created entity. - The Company has a limited operating history and has not generated revenues from its planned principal operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company currently has limited sales and marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. - The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. - The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“ U.S. GAAP The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., which contemplate continuation of the Company as a going concern. However, during the fiscal year ended December 31, 2016, the Company incurred a net loss of $ 766,072 445,232 231,996 The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $ 250,000 The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. - The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2016 and 2015, the Company didn’t have any Level 2 or 3 financial instruments. - The Company records impairment losses when indicators of impairment are present and undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Furthermore, the Company will make periodic assessments of technology and clinical testing to determine if it plans to continue to pursue the technology and if the license, patent or other rights have value. To date no impairment has been recorded. The Company will recognize revenue as it is earned as defined by U.S. GAAP. From Inception to December 31, 2016, there were no sales and revenue was not recognized. For the next several months, until clinical trials have successfully been completed, the Company does not anticipate there will be revenue to report. - Research and development will be the principal function of the Company. Research and development costs will be expensed as incurred. Expenses in the accompanying financial statements include certain costs which are directly associated with the Company’s research and development: 1. Erectile Dysfunction Technology based upon the use of stem cells. These costs, which consist primarily of monies paid for clinical trial expenses, materials and supplies and compensation costs amounted to $ 88,834 2. Infertility Treatment based upon implanting stem cells in the female reproductive system. The costs of acquiring an exclusive license of $ 12,640 The Company accounts for its stock-based compensation in accordance with Accounting Standards Codification (“ ASC The Company follows ASC 505-50, Equity-Based Payments to Non-Employees, for stock options and warrants issued to consultants and other non-employees. In accordance with ASC 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument, which is revalued at each reporting period, is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. – The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred income taxes are recognized for differences between financial reporting and tax bases of assets and liabilities at the enacted statutory tax rates in effect for the years in which the temporary differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. The Company evaluates the realizability of deferred tax assets and valuation allowances are provided when necessary to reduce net deferred tax assets to the amounts expected to be realized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The Company will recognize interest and penalties related to unrecognized tax benefits in the income tax provision in the accompanying statement of operations. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income taxes paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of relevant risks, facts and circumstances existing at that time. To the extent that the assessment of such tax positions change, the change in estimate is recorded in the period in which the determination is made. The Company follows Financial Accounting Standards Board (“ FASB EPS 500,000 500,000 The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

LICENSING AGREEMENTS

LICENSING AGREEMENTS	12 Months Ended
	Dec. 31, 2016
Licensing Agreements Disclosure [Abstract]
Licensing Agreements Disclosure [Text Block]	NOTE 2 – LICENSING AGREEMENTS ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 64,666,667 100,000 2025 9,124 90,876 10,000 Male Infertility License Agreement - The Company has acquired a royalty license from Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (“ LABIOMED The license was acquired for a cash payment of $ 5,000 323,333 1,000 0.01 1,800 1,800 7,800 The Company is subject to a 6 25 20,000 50,000 Multipotent Amniotic Fetal Stem Cells License Agreement - The Company estimates that the patent expires in February 2026 232 9,768 1,200 For the year ending December 31, 2017 $ 11,176 2018 11,176 2019 11,176 2020 11,176 2021 11,176 Thereafter $ 44,764

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 3 – RELATED PARTY TRANSACTIONS The Company has an agreement with CMH which obligates the Company to reimburse CMH $ 35,000 1,000,000 420,000 280,000 During the year ended December 31, 2016, the Company paid $ 3,000 During the year ended December 31, 2016, the Company entered into three note payable agreements with CMH in which the proceeds were used in operations. The notes payable were dated February 2, 2016 May 1, 2016 May 18, 2016 50,000 50,000 25,000 50,000 April 30, 2017 50,000 July 31, 2017 25,000 May 18, 2018 8 6,398 During the year ended December 31, 2016, CMH has advanced the Company $ 2,000 During the year ended December 31, 2016, the Company issued 300,000 shares of common stock and 30,000 30,000 See Note 2 for discussion of an additional related party transaction with CMH.

OPTIONS

OPTIONS	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 4 – OPTIONS The Company has reserved 2,000,000 Plan In July and September 2016, the Company granted 10 250,000 0.175 The options vest at a rate of 50,000 on each anniversary date of the respective grants. Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 7.27 Risk-free interest rate 1.42 % Expected volatility 89.49 % Common stock price $ 0.10 Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies. Stock based compensation for the year ended December 31, 2016 was $ 2,565 33,493 2021 Weighted Weighted Average Average Stock Options Exercise Price Life Remaining Outstanding, December 31, 2015 - $ - - Issued 500,000 0.18 10.00 Exercised - - - Expired - - - Outstanding, December 31, 2016 500,000 $ 0.18 9.65 Vested, December 31, 2016 - $ - - The weighted average grant-date fair value of the Company’s options issued during the year ended December 31, 2016 was approximately $0.10 per share.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 5 – STOCKHOLDERS’ DEFICIT In August 2016, the Company commenced a non-public offering of common stock at $ 0.10 one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering. 5,000,000 500,000 500,000 30,000 32,530 Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 3.00 Risk-free interest rate 0.86 % Expected volatility 102.59 % Common stock price $ 0.10 Weighted Weighted Average Average Warrants Exercise Price Life Remaining Outstanding, December 31, 2015 - $ - - Issued 500,000 0.10 3.00 Exercised - - - Expired - - - Outstanding, December 31, 2016 500,000 $ 0.10 2.82 Vested, December 31, 2016 500,000 $ 0.10 2.82 See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements. See Note 3 for discussion related to the issuance of common stock to a related party for cash.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 6 – INCOME TAXES 2016 2015 Income tax provision attributable to: Federal $ (199,179) $ - State and local (61,286) - Valuation allowance 260,464 - Net provision for income tax $ - $ - 2016 2015 Deferred tax asset attributable to: Net operating loss carryover $ 189,064 $ - Accrued management fees, related party 71,400 Valuation allowance (260,464) - Net deferred tax asset $ - $ - The primary difference between the statutory federal rate and the Company’s effective tax rate for the year ended December 31, 2016 was due to the 100% valuation allowance. As of December 31, 2016, the Company had federal and state net operating loss carryforwards of approximately $ 557,000 As of December 31, 2016 and 2015, the Company maintained a full valuation allowance on its net deferred tax assets. The valuation allowance was determined in accordance with the provisions of ASC 740, Accounting for Income Taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses required that a full valuation allowance be recorded against all net deferred tax assets. The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The Company files income tax returns in the U.S. and Arizona. All years presented remain subject to examination for U.S. federal and state purposes. The Company is not currently under examination in federal or state jurisdictions.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 7 – SUBSEQUENT EVENTS In accordance with ASC 855, management reviewed all material events through February 13, 2017, for

ORGANIZATION AND SUMMARY OF S14

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Risks and Uncertainties [Policy Text Block]	Risks and Uncertainties - The Company has a limited operating history and has not generated revenues from its planned principal operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company currently has limited sales and marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates - The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation - The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“ U.S. GAAP
Liquidity Policy [Policy Text Block]	Going Concern - The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., which contemplate continuation of the Company as a going concern. However, during the fiscal year ended December 31, 2016, the Company incurred a net loss of $ 766,072 445,232 231,996
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration Risks - The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $ 250,000
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents - The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments - The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2016 and 2015, the Company didn’t have any Level 2 or 3 financial instruments.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment - The Company records impairment losses when indicators of impairment are present and undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Furthermore, the Company will make periodic assessments of technology and clinical testing to determine if it plans to continue to pursue the technology and if the license, patent or other rights have value. To date no impairment has been recorded.
Revenue Recognition, Policy [Policy Text Block]	Revenue - The Company will recognize revenue as it is earned as defined by U.S. GAAP. From Inception to December 31, 2016, there were no sales and revenue was not recognized. For the next several months, until clinical trials have successfully been completed, the Company does not anticipate there will be revenue to report.
Research and Development Expense, Policy [Policy Text Block]	Research and Development - Research and development will be the principal function of the Company. Research and development costs will be expensed as incurred. Expenses in the accompanying financial statements include certain costs which are directly associated with the Company’s research and development: 1. Erectile Dysfunction Technology based upon the use of stem cells. These costs, which consist primarily of monies paid for clinical trial expenses, materials and supplies and compensation costs amounted to $ 88,834 2. Infertility Treatment based upon implanting stem cells in the female reproductive system. The costs of acquiring an exclusive license of $ 12,640
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation – The Company accounts for its stock-based compensation in accordance with Accounting Standards Codification (“ ASC The Company follows ASC 505-50, Equity-Based Payments to Non-Employees, for stock options and warrants issued to consultants and other non-employees. In accordance with ASC 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument, which is revalued at each reporting period, is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered.
Income Tax, Policy [Policy Text Block]	Income Taxes – The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred income taxes are recognized for differences between financial reporting and tax bases of assets and liabilities at the enacted statutory tax rates in effect for the years in which the temporary differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. The Company evaluates the realizability of deferred tax assets and valuation allowances are provided when necessary to reduce net deferred tax assets to the amounts expected to be realized. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The Company will recognize interest and penalties related to unrecognized tax benefits in the income tax provision in the accompanying statement of operations. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income taxes paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of relevant risks, facts and circumstances existing at that time. To the extent that the assessment of such tax positions change, the change in estimate is recorded in the period in which the determination is made.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“ FASB EPS 500,000 500,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

LICENSING AGREEMENTS (Tables)

LICENSING AGREEMENTS (Tables)	12 Months Ended
	Dec. 31, 2016
Licensing Agreements Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	As of December 31, 2016, future expected amortization of these assets is as follows: For the year ending December 31, 2017 $ 11,176 2018 11,176 2019 11,176 2020 11,176 2021 11,176 Thereafter $ 44,764

OPTIONS (Tables)

OPTIONS (Tables) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2016
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of each option award is estimated using the Black-Scholes valuation model. Assumptions used in calculating the fair value during the year ended December 31, 2016 were as follows: Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 7.27 Risk-free interest rate 1.42 % Expected volatility 89.49 % Common stock price $ 0.10
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Option activity for the year ended December 31, 2016 consists of the following: Weighted Weighted Average Average Stock Options Exercise Price Life Remaining Outstanding, December 31, 2015 - $ - - Issued 500,000 0.18 10.00 Exercised - - - Expired - - - Outstanding, December 31, 2016 500,000 $ 0.18 9.65 Vested, December 31, 2016 - $ - -

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables) - Warrant [Member]	12 Months Ended
	Dec. 31, 2016
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Assumptions used in calculating the fair value of the warrants during the year ended December 31, 2016 were as follows: Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 3.00 Risk-free interest rate 0.86 % Expected volatility 102.59 % Common stock price $ 0.10
Schedule of Share-based Compensation, Activity [Table Text Block]	Warrant activity for the year ended December 31, 2016 consists of the following: Weighted Weighted Average Average Warrants Exercise Price Life Remaining Outstanding, December 31, 2015 - $ - - Issued 500,000 0.10 3.00 Exercised - - - Expired - - - Outstanding, December 31, 2016 500,000 $ 0.10 2.82 Vested, December 31, 2016 500,000 $ 0.10 2.82

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The provision for income tax expense consists of the following at December 31, 2016 and 2015: 2016 2015 Income tax provision attributable to: Federal $ (199,179) $ - State and local (61,286) - Valuation allowance 260,464 - Net provision for income tax $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred tax assets consists of the following at December 31, 2016 and 2015: 2016 2015 Deferred tax asset attributable to: Net operating loss carryover $ 189,064 $ - Accrued management fees, related party 71,400 Valuation allowance (260,464) - Net deferred tax asset $ - $ -

ORGANIZATION AND SUMMARY OF S19

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	Dec. 31, 2015USD ($)	May 18, 2016USD ($)shares	Dec. 31, 2016USD ($)shares
Operating Income (Loss)	$ (500)		$ (766,072)
Working Capital Deficit			231,996
Cash, FDIC Insured Amount			250,000
Research and Development Expense	$ 0		85,334
Net Cash Provided by (Used in) Operating Activities			$ 445,232
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			500,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			500,000
Creative Medical Technologies, Inc [Member]
Due to Related Parties		$ 25,000
Stock Issued During Period, Shares, New Issues | shares		97,000,000
Stockholders' Equity Note, Stock Split, Conversion Ratio		6.466666
Stock Repurchased and Retired During Period, Shares | shares		15,100,000
Stock Repurchased and Retired During Period, Value		$ 5,000
Erectile Dysfunction Technology [Member]
Research and Development Expense			$ 88,834
LABIOMED [Member]
Research and Development Expense			$ 12,640

LICENSING AGREEMENTS (Details)

LICENSING AGREEMENTS (Details)	Dec. 31, 2016USD ($)
For the year ending December 31,
2,017	$ 11,176
2,018	11,176
2,019	11,176
2,020	11,176
2,021	11,176
Thereafter	$ 44,764

LICENSING AGREEMENTS (Details T

LICENSING AGREEMENTS (Details Textual) - USD ($)	Dec. 31, 2015	Feb. 02, 2016	Sep. 30, 2016	Dec. 31, 2016
Amortization of Intangible Assets	$ 0			$ 9,356
Payments to Acquire Intangible Assets	0			10,000
Finite-Lived Intangible Assets, Net	$ 0			100,644
Patents [Member]
Stock Issued During Period, Value, Purchase of Assets				100,000
Finite-Lived Intangible Assets, Net				90,876
Finite Lived Intangible Assets, Expected Annual Amortization				10,000
Licensing Agreements [Member]
Payments to Acquire Intangible Assets				5,000
Reimbursement of License fees				$ 1,800
Shares Issued, Price Per Share				$ 0.01
Royalty Expense				$ 7,800
Royalty Payment Percentage				6.00%
Non-Royalty Sublease Income Percentage				25.00%
Payments for Royalties			$ 20,000	$ 50,000
Finite-Lived Intangible Assets, Net				9,768
Finite Lived Intangible Assets, Expected Annual Amortization				$ 1,200
Licensing Agreements [Member] | Restricted Stock [Member]
Stock Issued During Period, Shares, Purchase of Assets				323,333
Stock Issued During Period, Value, Purchase of Assets				$ 1,000
Multipotent Amniotic Fetal Stem Cells License Agreement [Member] | Patents [Member]
Finite-Lived Intangible Asset, Expiration Period		2,026
Amortization of Intangible Assets				232
Creative Medical Health, Inc [Member] | Patents [Member]
Stock Issued During Period, Shares, Purchase of Assets		64,666,667
Stock Issued During Period, Value, Purchase of Assets		$ 100,000
Finite-Lived Intangible Asset, Expiration Period		2,025
Amortization of Intangible Assets				$ 9,124

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Management Fee Payable	$ 0	$ 280,000	$ 280,000
Proceeds from Related Party Debt	$ 0		2,500
Related Party Transaction, Expenses from Transactions with Related Party			420,000
Non Public Offering [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance or Sale of Equity		500,000
Creative Medical Health [Member]
Related Party Transaction [Line Items]
Management Fee Payable		$ 280,000	280,000
Reimbursement of Management Fees			$ 35,000
Maximum Number of Shares to be Issued		1,000,000	1,000,000
Line of Credit Facility, Interest Rate During Period			8.00%
Interest Payable, Current		$ 6,398	$ 6,398
Proceeds from Related Party Debt			2,000
Number Of Warrants Issued			30,000
Creative Medical Health [Member] | Non Public Offering [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance or Sale of Equity			30,000
Creative Medical Health [Member] | February Note [Member]
Related Party Transaction [Line Items]
Proceeds from Lines of Credit			$ 50,000
Line of Credit Facility, Initiation Date			Feb. 2, 2016
Line of Credit Facility, Maximum Borrowing Capacity		50,000	$ 50,000
Line of Credit Facility, Expiration Date			Apr. 30, 2017
Creative Medical Health [Member] | May Note One [Member]
Related Party Transaction [Line Items]
Proceeds from Lines of Credit			$ 50,000
Line of Credit Facility, Initiation Date			May 1, 2016
Line of Credit Facility, Maximum Borrowing Capacity		50,000	$ 50,000
Line of Credit Facility, Expiration Date			Jul. 31, 2017
Creative Medical Health [Member] | May Note Two [Member]
Related Party Transaction [Line Items]
Proceeds from Lines of Credit			$ 25,000
Line of Credit Facility, Initiation Date			May 18, 2016
Line of Credit Facility, Maximum Borrowing Capacity		$ 25,000	$ 25,000
Line of Credit Facility, Expiration Date			May 18, 2018
Officer [Member]
Related Party Transaction [Line Items]
Payments for Other Fees			$ 3,000

OPTIONS (Details)

OPTIONS (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2016$ / shares
Annual dividend yield	0.00%
Expected life (years)	7 years 3 months 7 days
Risk-free interest rate	1.42%
Expected volatility	89.49%
Common stock price	$ 0.10

OPTIONS (Details 1)

OPTIONS (Details 1) - Employee Stock Option [Member] - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option, Outstanding, December 31, 2015		0
Issued	250,000	500,000
Exercised		0
Expired		0
Outstanding, December 31, 2016		500,000
Vested, December 31, 2016		0
Weighted Average Exercise Price, Outstanding, December 31, 2015		$ 0
Weighted Average Exercise Price, Issued	$ 0.175	0.18
Weighted Average Exercise Price, Exercised		0
Weighted Average Exercise Price, Expired		0
Weighted Average Exercise Price, Outstanding, December 31, 2016		0.18
Weighted Average Exercise Price, Vested, December 31, 2016		$ 0
Weighted Average Life Remaining, Issued		10 years
Weighted Average Life Remaining, Outstanding, December 31, 2016		9 years 7 months 24 days

OPTIONS (Details Textual)

OPTIONS (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	May 18, 2016
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 33,493
Employee Service Share-based Compensation, Nonvested Awards, Expiration Period		2,021
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense		$ 2,565
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	250,000	500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.175	$ 0.18
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	The options vest at a rate of 50,000 on each anniversary date of the respective grants.
Stock Incentive Plan 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			2,000,000

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2016$ / shares
Annual dividend yield	0.00%
Expected life (years)	3 years
Risk-free interest rate	0.86%
Expected volatility	102.59%
Common stock price	$ 0.10

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details 1) - Warrant [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants, Outstanding, December 31, 2015 | shares	0
Warrants, Issued | shares	500,000
Warrants, Exercised | shares	0
Warrants, Expired | shares	0
Warrants, Outstanding, December 31, 2016 | shares	500,000
Warrants, Vested, December 31, 2016 | shares	500,000
Weighted Average Exercise Price, Outstanding, December 31, 2015 | $ / shares	$ 0
Weighted Average Exercise Price, Issued | $ / shares	0.10
Weighted Average Exercise Price, Exercised | $ / shares	0
Weighted Average Exercise Price, Expired | $ / shares	0
Weighted Average Exercise Price, Outstanding, December 31, 2016 | $ / shares	0.10
Weighted Average Exercise Price, Vested, December 31, 2016 | $ / shares	$ 0.10
Weighted Average Life Remaining, Issued	3 years
Weighted Average Life Remaining, Outstanding, December 31, 2016	2 years 9 months 25 days
Weighted Average Life Remaining, Vested, December 31, 2016	2 years 9 months 25 days

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details Textual) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Aug. 31, 2016	Aug. 06, 2016
Class of warrant or Right, Conversion Ratio		one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering.
Non Public Offering [Member]
Stock Issued During Period, Shares, New Issues	5,000,000
Proceeds from Issuance or Sale of Equity	$ 500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				500,000
Warrants Not Settleable in Cash, Fair Value Disclosure				$ 32,530
Shares Issued, Price Per Share			$ 0.10
Non Public Offering [Member] | Creative Medical Health [Member]
Proceeds from Issuance or Sale of Equity	$ 30,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income tax provision attributable to:
Federal	$ (199,179)	$ 0
State and local	(61,286)	0
Valuation allowance	260,464	0
Net provision for income tax	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax asset attributable to:
Net operating loss carryover	$ 189,064	$ 0
Accrued management fees, related party	71,400
Valuation allowance	(260,464)	0
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual)	Dec. 31, 2016USD ($)
Operating Loss Carryforwards	$ 557,000